Related Experiment Video

Updated: May 8, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

Oncogenic function of p34SEI-1 via NEDD4‑1‑mediated PTEN ubiquitination/degradation and activation of the PI3K/AKT

Samil Jung1, Chengping Li, Dongjun Jeong

  • 1Department of Biological Science and Research Center for Women's Diseases, Sookmyung Women's University, Seoul 140-742, Republic of Korea.

International Journal of Oncology
|August 24, 2013
PubMed

Insights

The oncoprotein p34(SEI-1) promotes cancer by downregulating the tumor suppressor PTEN, activating the PI3K/AKT pathway, and increasing NEDD4-1 expression. Its levels correlate with breast cancer progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • p34(SEI-1) is a recently identified oncoprotein with significant biological roles.
  • The Phosphatidylinositol 3-kinase/AKT (PI3K/AKT) signaling pathway is crucial in cell survival and cancer development.
  • PTEN acts as a tumor suppressor by negatively regulating the PI3K/AKT pathway.

Purpose of the Study:

  • To investigate the role of p34(SEI-1) in cancer cell survival and tumorigenesis.
  • To elucidate the molecular mechanisms by which p34(SEI-1) influences the PTEN/PI3K/AKT pathway.
  • To examine the relationship between p34(SEI-1) and NEDD4-1 expression in breast cancer.

Main Methods:

  • Analysis of gene and protein expression levels.
  • Investigation of signaling pathway activation.
  • Assessment of protein subcellular localization.
  • Correlation studies in patient tumor tissues.

Main Results:

  • p34(SEI-1) enhances cancer cell survival and promotes tumorigenesis.
  • p34(SEI-1) downregulates PTEN, leading to PI3K/AKT pathway activation.
  • p34(SEI-1) positively regulates NEDD4-1 expression transcriptionally and post-translationally.
  • Expression of p34(SEI-1) and NEDD4-1 is coordinated in breast cancer tissues.
  • p34(SEI-1) influences PTEN's subcellular localization.

Conclusions:

  • p34(SEI-1) is an oncoprotein that drives cancer progression via PTEN downregulation and PI3K/AKT pathway activation.
  • NEDD4-1 is a downstream target of p34(SEI-1), and their coordinated expression is relevant in breast cancer.
  • Targeting p34(SEI-1) or its downstream effectors may offer therapeutic strategies for cancer.

More Related Videos

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...